Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dontinurad · 1 trial · 2 indications
To evaluate the Cmax of dotinurad 2mg, dotinturad 4mg, and allopurinol 300mg
To evaluate the AUC of dotinurad 2mg, dotinturad 4mg, and allopurinol 300mg
To evaluate the Tmax of dotinurad 2mg, dotinturad 4mg, and allopurinol 300mg
To evaluate the T1/2 of dotinurad 2mg, dotinturad 4mg, and allopurinol 300mg
| Arm | Type | Description |
|---|---|---|
| dotinurad 2mg | EXPERIMENTAL | dotinurad 2mg q.d. |
| dotinurad 4mg | EXPERIMENTAL | dotinurad 4mg q.d. |
| Name | Type | Description |
|---|---|---|
| dontinurad | DRUG | dotinurad alone |
| dotinurad + allopurinol | DRUG | dotinurad + allopurinol 300mg |
| allopurinol | DRUG | allopurinol 300 mg alone |
Inclusion Criteria: * 1\. In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements. 2\. Patients with a diagnosis of gout based on American College of Rheumatology criteria (1997). Patients must fulfill at least 3 of the following, with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Protalix BioTherapeutics, Inc. (DE) | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE1 | Pegylated Recombinant Candida Utilis Uricase |